By Hassan Zaggi
The Federal Government has called on PhArmacoVIgilance Africa (PAVIA) partners to strengthen Pharmacovigilance systems in Nigeria , especially those related to NTBLCP.
The Minister of Health, Prof Isaac Adewole, gave the charge at the opening ceremony of Nigeria Specific Meeting on PAVIA in Abuja.
The meeting was organised by NAFDAC in collaboration with NTLCP, IHVN, University of Benin and KNCV Tuberculosis Foundation.
https://ssl.gstatic.com/ui/v1/icons/mail/images/cleardot.gifPhArmacoVIgilance Africa (PAVIA) is a consortium which was recently funded by the European Developing countries Clinical Trials Partnership (EDCTP).
The PAVIA projects are aimed at strengthening pharmacovigilance (PV) in four African countries including Ethiopia, Nigeria, Swaziland and Tanzania.
To achieve this aim, collaborative support will be harnessed across several institutions in Europe and Africa.
Represented by the Director, Food and Drug Services in the Ministry,Pharm. Mashood Lawal, the minister disclosed that government had developed policies for stakeholders in health sectors to work concertedly to detect, document and report adverse drug reactions associated with use of medicines in the country.
“I will like to use this opportunity to call on all PAVIA partners to strengthen Pharmacovigilance systems in Nigeria particularly those related to NTBLCP.
“PAVIA partners should also effectively detect and report adverse reactions that may be associated with new drugs for Multi-Drug Resistant (MDR) Tuberculosis.
“This is pertinent because Nigeria is classified amongst the 14 countries with high burden of MDR-TB and TB/HIV disease.
“TB incidence rate in 2016 indicates 219 per 100,000 population with 407,000 estimated TB cases.
“And mortality rate of all forms of TB excluding HIV with TB stands at 62 per 100,000 population,” Adewole noted.
Speaking, the Director General of NAFDAC, Prof. Moji Adeyeye said that PAVIA project was to strengthen Pharmacovigilance (PV) in four African countries of Ethiopia, Nigeria, Swaziland and Tanzania.
According to her, the project would strengthen governance of PV systems by strengthening regulatory and organisational structures as well as defining clear roles and responsibilities for all stakeholders.
“It will improve efficiency and effectiveness of National surveillance of adverse drug reaction and implementation of tools and technologies for their detection, reporting, analysis and dissemination.
“It will build capacity and skills to sufficiently conduct safety monitoring activities throughout the country” she reiterated.